GR1803 for Multiple Myeloma with Soft Tissue Spread
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental drug called GR1803 for people with multiple myeloma that has spread to soft tissue areas outside the bone. The goal is to see if it can help shrink these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have multiple myeloma that has spread to areas outside the bone marrow, called extramedullary plasmacytoma.
- You are able to care for yourself and are up and about (ECOG score 0 to 2).
- You have not been treated with a therapy that targets the BCMA protein before.
- Your multiple myeloma does not involve the brain or spinal cord, and you do not have other rare plasma cell disorders like plasma cell leukemia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
This trial tests a new drug, SHR-5421, for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests a new combination therapy (GR1803 plus an anti-CD38 monoclonal antibody) for people with multiple myeloma who have already tried lenalidomide and a proteasome inhibitor. It aims to see if the combination is safe and helps control the cancer.
Hear when a new Multiple Myleoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.